Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
NCT07526974Phase 3Not yet recruiting
- Sponsor
- Caliway Biopharmaceuticals
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of CBL-514 in subcutaneous fat, sponsored by Caliway Biopharmaceuticals. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
CBL-514
03
Conditions
subcutaneous fat
Beyond the preview
Go deeper on NCT07526974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07526974.